Share

April 2016; 3 (2) ArticleOpen Access

The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients

Amandine Mathias, Guillaume Perriard, Mathieu Canales, Fanny Vuilleumier, Gaetano Perrotta, Myriam Schluep, Renaud Du Pasquier
First published February 10, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000209
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
776

Share

Article Information

vol. 3 no. 2 e209
DOI: 
https://doi.org/10.1212/NXI.0000000000000209
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received September 22, 2015
  • Accepted in final form December 27, 2015
  • First Published February 10, 2016.
Copyright & Usage: 
© 2016 American Academy of Neurology This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Author Disclosures

    1. Amandine Mathias, PhD,
    2. Guillaume Perriard, PhD,
    3. Mathieu Canales,
    4. Fanny Vuilleumier, BS,
    5. Gaetano Perrotta, MD,
    6. Myriam Schluep, MD and
    7. Renaud Du Pasquier, MD
  1. Amandine Mathias, PhD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Guillaume Perriard, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Mathieu Canales,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Fanny Vuilleumier, BS,
    5. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gaetano Perrotta, MD,
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Myriam Schluep, MD and
    7. Scientific Advisory Boards:

    1. Participation to scientific advisory boards from Biogen, Genzyme, Merck-Serono, Novartis, and Sanofi-Aventis;compensation was paid to the institution.

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Participation to meetings organized by from Biogen, Genzyme, Merck-Serono, Novartis, and Sanofi-Aventis; compensation was paid to the institution.

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Episodic consultancies for Biogen, Merck Serono,Novartis, Genzyme, Sanofi-Aventis; compensation was paid to the institution.

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Unrestricted grants from Merck Serono, Novartis and Biogen.

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Renaud Du Pasquier, MD
    8. Scientific Advisory Boards:

    1. Biogen, Genzyme

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. Sanofi, Genzym

    Editorial Boards:

    1. Editorial boards of Journal of Neurovirology

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Swiss Society for Multiple Sclerosis, Novartis Investigator-initiated trial

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Laboratory of Neuroimmunology, Center of Research in Neurosciences (A.M., G. Perriard, M.C., F.V., R.D.P.), and Service of Neurology (G. Perrotta, M.S., R.D.P.), Department of Clinical Neurosciences, CHUV, Lausanne, Switzerland.
  1. Correspondence to Dr. Du Pasquier: Renaud.Du-Pasquier{at}chuv.ch
View Full Text

Article usage

Article usage: February 2016 to August 2023

AbstractFullPdfSource
Feb 20161864139Highwire
Feb 2016022pmc
Mar 201630912226Highwire
Mar 201605836pmc
Apr 20161981521Highwire
Apr 201602911pmc
May 201690413Highwire
May 201601711pmc
Jun 20164768Highwire
Jun 201601410pmc
Jul 201647512Highwire
Jul 2016062pmc
Aug 20164429Highwire
Aug 20160269pmc
Sep 20163925Highwire
Sep 20160182pmc
Oct 20162323Highwire
Oct 20160155pmc
Nov 20161953Highwire
Nov 20160184pmc
Dec 20162111Highwire
Dec 2016073pmc
Jan 20173964Highwire
Jan 2017060pmc
Feb 20171324Highwire
Feb 2017084pmc
Mar 20171913Highwire
Mar 2017081pmc
Apr 20171323Highwire
Apr 2017476pmc
May 201719102Highwire
May 201701314pmc
Jun 2017925Highwire
Jun 2017488pmc
Jul 2017830Highwire
Jul 2017255pmc
Aug 2017971Highwire
Aug 2017277pmc
Sep 2017812Highwire
Sep 20172129pmc
Oct 20171111Highwire
Oct 2017133pmc
Nov 20171165Highwire
Nov 20175912pmc
Dec 2017136Highwire
Jan 2018142Highwire
Feb 2018046Highwire
Mar 2018064Highwire
Apr 201802311Highwire
Apr 20183810pmc
May 20181178Highwire
Jun 20180134Highwire
Jun 2018166pmc
Jul 20180124Highwire
Aug 20181265Highwire
Aug 2018056pmc
Sep 20181182Highwire
Oct 20181305Highwire
Nov 20182591Highwire
Dec 20183925Highwire
Jan 20192813Highwire
Feb 20190748Highwire
Mar 201911075Highwire
Apr 201911179Highwire
May 20193957Highwire
Jun 20192585Highwire
Jul 201911439Highwire
Aug 201912437Highwire
Sep 201912242Highwire
Oct 201902511Highwire
Nov 201901715Highwire
Dec 201911036Highwire
Jan 2020093Highwire
Feb 20200118Highwire
Mar 2020176Highwire
Apr 2020072Highwire
May 20200232Highwire
Jun 20200103Highwire
Jul 20200112Highwire
Aug 2020142Highwire
Sep 20202154Highwire
Oct 20201289Highwire
Nov 202011013Highwire
Dec 2020294Highwire
Jan 20211108Highwire
Feb 2021074Highwire
Mar 2021031Highwire
Apr 2021083Highwire
May 20213104Highwire
Jun 20211162Highwire
Jul 20211910Highwire
Aug 20211216Highwire
Sep 20210104Highwire
Oct 202142224Highwire
Nov 202111013Highwire
Dec 20211153Highwire
Jan 2022022Highwire
Feb 20221147Highwire
Mar 20221186Highwire
Apr 2022067Highwire
May 202221012Highwire
Jun 20223139Highwire
Jul 2022183Highwire
Aug 20224195Highwire
Sep 202232915Highwire
Oct 202222611Highwire
Nov 202264815Highwire
Dec 20222929Highwire
Jan 20233237Highwire
Feb 20232208Highwire
Mar 20230144Highwire
Apr 202321410Highwire
May 2023297Highwire
Jun 2023074Highwire
Jul 2023134Highwire
Aug 2023395Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles